429 related articles for article (PubMed ID: 28592790)
1. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
3. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY
Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493
[TBL] [Abstract][Full Text] [Related]
5. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Garofalo M; Romano G; Di Leva G; Nuovo G; Jeon YJ; Ngankeu A; Sun J; Lovat F; Alder H; Condorelli G; Engelman JA; Ono M; Rho JK; Cascione L; Volinia S; Nephew KP; Croce CM
Nat Med; 2011 Dec; 18(1):74-82. PubMed ID: 22157681
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer.
Wang F; Meng F; Wong SCC; Cho WCS; Yang S; Chan LWC
Ther Adv Respir Dis; 2020; 14():1753466620915156. PubMed ID: 32552611
[TBL] [Abstract][Full Text] [Related]
7. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
[TBL] [Abstract][Full Text] [Related]
8. MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene.
Li Y; Zhang H; Li Y; Zhao C; Fan Y; Liu J; Li X; Liu H; Chen J
Mol Carcinog; 2018 Jan; 57(1):125-136. PubMed ID: 28940757
[TBL] [Abstract][Full Text] [Related]
9. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Zhou YM; Liu J; Sun W
Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
11. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
12. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
13. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
14. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
15. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
16. Circular RNA hsa_circ_0008305 (circPTK2) inhibits TGF-β-induced epithelial-mesenchymal transition and metastasis by controlling TIF1γ in non-small cell lung cancer.
Wang L; Tong X; Zhou Z; Wang S; Lei Z; Zhang T; Liu Z; Zeng Y; Li C; Zhao J; Su Z; Zhang C; Liu X; Xu G; Zhang HT
Mol Cancer; 2018 Sep; 17(1):140. PubMed ID: 30261900
[TBL] [Abstract][Full Text] [Related]
17. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
18. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
[TBL] [Abstract][Full Text] [Related]
19. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
